Log in

NASDAQ:IMMPIMMUTEP LTD/S Stock Price, Forecast & News

$1.08
-0.01 (-0.92 %)
(As of 06/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.08
Now: $1.08
$1.12
50-Day Range
$0.92
MA: $1.06
$1.31
52-Week Range
$0.53
Now: $1.08
$3.10
Volume124,089 shs
Average Volume618,585 shs
Market Capitalization$42.12 million
P/E RatioN/A
Dividend YieldN/A
Beta2.14
Immutep Limited, a biotechnology company, engages in the research, development, and commercialization of biological products. The company develops immunotherapeutic products for the treatment of cancer and autoimmune diseases. Its therapeutics are based on the lymphocyte activation gene-3 (LAG-3) Ig fusion protein, a cell surface molecule that plays a role in regulating T cells. The company's lead product candidate is eftilagimod alpha (efti) with KEYTRUDA therapy, an antigen presenting cell activator, which is in a Phase IIb clinical trial as a chemoimmunotherapy for metastatic breast cancer, as well as in a Phase I combination therapy trial in metastatic melanoma. Its other products include IMP731, a LAG-3 depleting antibody, which is in a Phase I clinical trial for use in autoimmune diseases; IMP701, a LAG-3 antagonist antibody that is in a Phase I/II clinical trial, which is used for the treatment of cancer; and IMP761, an agonist of LAG-3 for treating autoimmune diseases. The company has operations in Europe, Australia, and the United States. Immutep Limited has a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany, and Pfizer Inc., to evaluate the combination of efti with avelumab, a human anti-PD-L1 antibody, in patients with advanced solid malignancies; and partnerships with GlaxoSmithKline, Novartis, and EOC Pharma for the development of LAG-3 product candidates. The company was formerly known as Prima BioMed Ltd and changed its name to Immutep Limited in November 2017. Immutep Limited is headquartered in Sydney, Australia.
Read More
IMMUTEP LTD/S logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.28 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMMP
CUSIPN/A
Phone61-2-8315-7003

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.36 million
Book Value$0.51 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$42.12 million
Next Earnings DateN/A
OptionableNot Optionable

Receive IMMP News and Ratings via Email

Sign-up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.

IMMUTEP LTD/S (NASDAQ:IMMP) Frequently Asked Questions

How has IMMUTEP LTD/S's stock been impacted by COVID-19 (Coronavirus)?

IMMUTEP LTD/S's stock was trading at $2.13 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, IMMP stock has decreased by 49.3% and is now trading at $1.08. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IMMUTEP LTD/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMMUTEP LTD/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMMUTEP LTD/S.

What price target have analysts set for IMMP?

1 brokers have issued 12 month price targets for IMMUTEP LTD/S's shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate IMMUTEP LTD/S's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 85.2% from the stock's current price. View analysts' price targets for IMMUTEP LTD/S.

What are Wall Street analysts saying about IMMUTEP LTD/S stock?

Here are some recent quotes from research analysts about IMMUTEP LTD/S stock:
  • 1. Maxim Group analysts commented, "Immutep announced that it has received a £4M (~$5M) milestone payment from GlaxoSmithKline (GSK – NR) related to the initiation of dosing in the P2 trial for GSK2831781 (derived from IMP731) in ulcerative colitis. Immutep is eligible to receive up to £64M (~$79M) in development milestones as well as single digit royalties. Runway should extend into CY21. In addition to the $5M milestone, Immutep has also raised July financing. The financing consisted of a A$4M private placement for ~190M shares (~1.9M A$6M entitlement offer for ~290M shares (~2.9M ADR), both at A$0.021 per share (~ $1.42/ADR). We estimate the company has ~$18M of cash on hand. As such the company should be positioned to reach key catalysts which, if positive, should support a higher valuation." (9/24/2019)
  • 2. According to Zacks Investment Research, "Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the U.S. Immutep Limited, formerly known as Prima BioMed Ltd, is headquartered in Sydney, Australia. " (9/5/2019)

Has IMMUTEP LTD/S been receiving favorable news coverage?

Headlines about IMMP stock have been trending somewhat positive this week, InfoTrie reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IMMUTEP LTD/S earned a news sentiment score of 2.0 on InfoTrie's scale. They also gave media stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View the latest news aboutIMMUTEP LTD/S.

Who are some of IMMUTEP LTD/S's key competitors?

What other stocks do shareholders of IMMUTEP LTD/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IMMUTEP LTD/S investors own include CHF Solutions (CHFS), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Agile Therapeutics (AGRX), Amarin (AMRN), Vaxart (VXRT), Crispr Therapeutics (CRSP), Anavex Life Sciences (AVXL), Gilead Sciences (GILD) and Protalix Biotherapeutics (PLX).

Who are IMMUTEP LTD/S's key executives?

IMMUTEP LTD/S's management team includes the following people:
  • Mr. Marc Voigt, Exec. Director, CEO, CFO & Chief Bus. Officer (Age 46)
  • Ms. Deanne Miller, COO, Gen. Counsel & Company Sec. (Age 42)
  • Dr. Frédéric Triebel, Chief Scientific Officer & Chief Medical Officer (Age 64)
  • Mr. Jay R. Campbell, Chief Bus. Officer
  • Mr. David Fang, Fin. Director & Assistant Company Sec.

What is IMMUTEP LTD/S's stock symbol?

IMMUTEP LTD/S trades on the NASDAQ under the ticker symbol "IMMP."

Who are IMMUTEP LTD/S's major shareholders?

IMMUTEP LTD/S's stock is owned by many different retail and institutional investors. Top institutional shareholders include Morgan Stanley (0.34%).

Which institutional investors are buying IMMUTEP LTD/S stock?

IMMP stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley.

How do I buy shares of IMMUTEP LTD/S?

Shares of IMMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMMUTEP LTD/S's stock price today?

One share of IMMP stock can currently be purchased for approximately $1.08.

How big of a company is IMMUTEP LTD/S?

IMMUTEP LTD/S has a market capitalization of $42.12 million and generates $5.36 million in revenue each year.

What is IMMUTEP LTD/S's official website?

The official website for IMMUTEP LTD/S is www.immutep.com.

How can I contact IMMUTEP LTD/S?

IMMUTEP LTD/S's mailing address is LEVEL 12 95 PITT STREET, SYDNEY C3, 2000. The biotechnology company can be reached via phone at 61-2-8315-7003 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.